(Q71765806)
Statements
The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors (English)
W Van den Bogaert
E van der Schueren
J C Horiot
M De Vilhena
S Schraub
V Svoboda
G Arcangeli
M de Pauw